Aurobindo Pharma arm gets Health Canada nod for Dyrupeg biosimilarAurobindo Pharma arm gets Health Canada nod for Dyrupeg biosimilar

Introduction

Leading pharmaceutical group subsidiary has received Health Canada approval for its pegylated filgrastim biosimilar, adding to existing regulatory clearances in European and UK markets.

Also Read: LKP Finance hits 5% upper circuit after trademark license pact with Vouchagram India

Share price movement of Aurobindo Pharma

On January 9, 2026, Aurobindo Pharma Ltd opened at ₹1,199.30, down 0.62% from its previous close of ₹1,206.80. The stock touched a high of ₹1,210.00 (up 0.27%) and a low of ₹1,188.00. By 3:56 PM, it traded at ₹1,195.70, down 0.92%, with a market capitalisation of ₹69,446.45 crore.

Aurobindo Pharma Arm Gets Health Canada NOC

Aurobindo Pharma Limited said its wholly owned subsidiary CuraTeQ Biologics has received a Notice of Compliance from Health Canada for Dyrupeg, a pegylated filgrastim biosimilar.

The approval was granted by Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate after review confirming Dyrupeg meets safety, efficacy, quality, and biosimilarity standards.

Dyrupeg earlier received marketing authorisation in the European Union and the UK. CuraTeQ Biologics currently has three additional biosimilar applications under review with Health Canada.

Stock performance of Aurobindo Pharma for Period of 1 week, 6 months, and 1 year

Aurobindo Pharma Ltd declined 0.77% over the past week, gained 7.23% in six months, and fell 3.39% over the past one year.

Also Read: Bhel begins supply of key tech for Vande Bharat sleeper trains, here’s how

Shareholding pattern of Aurobindo Pharma

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	51.80%	51.80%	51.80%
FII	14.20%	14.40%	15.30%
DII	27.60%	27%	26.20%
Public	6%	6.90%	6.60%

About Aurobindo Pharma

Aurobindo Pharma Ltd (NSE: AUROPHARMA) manufactures and markets active pharmaceutical ingredients, generic medicines, and related pharmaceutical services across domestic and international markets.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs